Kristin Horwood ACNP-BC, AOCNP, MSN VEXAS Syndrome Overview VEXAS syndrome is a unique adult-onset disease with several varying clinical signs and symptoms. It is important
Tasha Nathan – Patient I was two weeks away from my 30th birthday when I found myself sitting in a hospital bed, watching the sunrise
Julia Lewin, PharmD, BCOP, BCPS Clinical trials are essential for advancing cancer treatments and improving patient outcomes. There is evidence that survival rates are higher
Ebele Ezenwa, DNP, APRN, APRN, FNP-C Throughout my career as an advanced practice provider (APP), I have had the opportunity to attend several in-person medical
Part 2 of a two-part article on caring for adolescents and young adults in oncology At an age when most young people are charting their
Krystle Zuniga, PhD, RD, CSO, LD Despite a wealth of information on the relationship between modifiable lifestyle factors and cancer incidence, there is a limited
Kristin Horwood ACNP-BC, AOCNP, MSN VEXAS Syndrome Overview VEXAS syndrome is a unique adult-onset disease with several varying clinical signs and symptoms. It is important for hematology/oncology advanced practice providers (APPs) to be aware of VEXAS syndrome as it is associated with several hematological disorders. V (vacuoles), E (E1 enzyme), X (X-linked), A (autoinflammatory), S (somatic mutation in ubiquitin-like modifier-activating enzyme 1 [UBA1] gene)1 syndrome was only recently described in 2020 as a new category of hemato-inflammatory diseases. This occurs from myeloid-driven inflammation arising from somatic mutations of the stem cell; in this case, mutations of the UBA1 gene.2 The syndrome is characterized by severe autoinflammation, which commonly presents with vasculitis, skin rash, polychondritis, arthritis, pulmonary inflammation, and constitutional symptoms. In a case series of 9 men with VEXAS syndrome, 88% had refractory constitutional symptoms that began 4 years prior to diagnosis.3 The diagnosis of VEXAS syndrome includes evidence of
Jenny Veliz-Urzua, DNP, MBA, FNP-BC, RNFA When I started my career, I was set on primary care. I was motivated by the benefits of disease prevention and early intervention in healthcare delivery. I never considered oncology. Truthfully, the oncology specialty chose me. There was a job opportunity at the start
Kelly Goodwin, NP It was the middle of the night Saturday, March 4, 2000, and I had been lying, not sleeping, on the mattress my sisters and I had dragged onto the floor of my parents’ room nearly 2 weeks prior. I heard my mother whisper, “He’s gone.” My father
Professional development may or may not help advanced practice providers in oncology climb the career ladder, but it will make your career more rewarding, according to speakers at a session devoted to the topic at the 2023 APP Oncology Summit in Scottsdale, Ariz. The session focused on strategies that can
Kristin Horwood ACNP-BC, AOCNP, MSN VEXAS Syndrome Overview VEXAS syndrome is a unique adult-onset disease with several varying clinical signs and symptoms. It is important for hematology/oncology advanced practice providers (APPs) to
Bethany Pan,, PharmD, Ryan Beechinor, PharmD, BCPS, BCOP Metastatic melanoma presents as a highly immunogenic form of cancer characterized by extensive mutational load and variations within and between tumors. This unique immunogenic
Beth Sandy, MSN, CRNP, FAPO The most common type of squamous cell carcinoma of the head and neck (SCCHN) is oropharyngeal cancer, which arises from the back one-third of the throat, mainly
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, and Amy Barker, MSN, APRN, FNP-C We have witnessed dismal overall outcomes in individuals with relapsed and/or refractory (R/R) multiple myeloma (MM) for many years. However, the
Manali Bhave, MD Triple-negative breast cancer (TNBC) accounts for 15% to 20% of all breast cancer cases1 and is characterized by aggressive disease associated with early recurrence and high mortality. Current advances
Sijimol Mathew, DNP, APRN, ACNP-BC Insulinomas originate from the uncontrolled growth of pancreatic beta cells. Chronic and recurrent hypoglycemia lowers the patient’s threshold to hypoglycemic insults; additionally, early morning hypoglycemia makes insulinoma
Julia Lewin, PharmD, BCOP, BCPS Clinical trials are essential for advancing cancer treatments and improving patient outcomes. There is evidence that survival rates are higher
Part 2 of a two-part article on caring for adolescents and young adults in oncology At an age when most young people are charting their
Sara E. Stevens, CNP As a young child, I remember thinking I would be a nurse when I grew up, in part due to aunts
Part 4 of an ongoing series David Letsa, MD Artificial intelligence (AI) is increasingly being used in healthcare to improve patient outcomes and streamline routine
Cancer is a formidable adversary, and for the estimated 86,000 individuals between the ages of 15 and 39 at initial diagnosis in 2023 in the
Part 3 of an ongoing series David Letsa, MD Integrating artificial intelligence (AI) and deep learning into the diagnostic process has begun to transform the
Beth Sandy, MSN, CRNP, FAPO In The Oncology Connection, we have had 2 recent articles addressing good patient communication strategies. “Language Matters” reviewed how we
Part 2 of an ongoing series David Letsa, MD Cancer continues to be one of the leading causes of death worldwide. Although there is progress
Tasha Nathan – Patient I was two weeks away from my 30th birthday when I found myself sitting in a hospital bed, watching the sunrise over Boston. What was supposed to be
Bethany Sterling MSN, CRNP, ANP-BC, AOCNP What are IPMNS of the pancreas? Intraductal papillary mucinous neoplasms (IPMNS) are benign mucin-producing neoplasms found in the main duct and/or side branch ducts of the
Bethany Pan,, PharmD, Ryan Beechinor, PharmD, BCPS, BCOP Metastatic melanoma presents as a highly immunogenic form of cancer characterized by extensive mutational load and variations within and between tumors. This unique immunogenic
Beth Sandy, MSN, CRNP, FAPO The most common type of squamous cell carcinoma of the head and neck (SCCHN) is oropharyngeal cancer, which arises from the back one-third of the throat, mainly
Kristin Horwood ACNP-BC, AOCNP, MSN VEXAS Syndrome Overview VEXAS syndrome is a unique adult-onset disease with several varying clinical signs and symptoms. It is important for hematology/oncology advanced practice providers (APPs) to
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, and Amy Barker, MSN, APRN, FNP-C We have witnessed dismal overall outcomes in individuals with relapsed and/or refractory (R/R) multiple myeloma (MM) for many years. However, the
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP The bispecific antibodies have shown an impressive response rate with tolerable safety profile in patients with relapsed and refractory multiple myeloma (R/R MM). The Food and Drug
Stephen Michael Clark, PharmD BCOP There have been some exciting advancements in immunotherapy for cancer in the past year, particularly hematologic malignancies. One such advancement is a group of therapies known as
Beth Sandy, MSN, CRNP — Editor-in-Chief
Haleigh Mistry, MS, PA-C
Laura Alwan, PharmD, BCOP
Kelly Goodwin, NP
Ryan Beechinor, PharmD, BCOP
Jenny Veliz-Urzua, DNP, MSN, FNP-BC
Carol Peyton Bryant, DNP, RN, ACNP, CCRN
Victoria Nachar, PharmD, BCOP
